Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Jedi this is the biggest crock of bullshit imaginable. He has followed through on absolutely nothing. This POS is nothing but a master of bullshitting that things are about to happen and then nothing happens. It is impossible to put forth even the most minimal effort and not be productive at all. Remember the DR deal that was supposed to be done in autumn of '21 or the Mexican deal a year ago? This anal cavity is nothing but a lying piece of crap. Really, after all this, you don't realize it is all bullshit? And you expect anyone else to buy it?
Unfortunately, it doesn't work that way. SH have no (zero) influence over that. It's just wishful thinking. All we can really do is HOPE that Arthur is sincere and has the capability to execute the initiatives he laid out in the last PR. So for now.... We Wait and Wait. Best to put this on the back burner and give it time to work out. It may take all of 2023. Meanwhile, there are other penny stocks to play with that have shorter term promise.
https://www.weny.com/story/47865534/quanta-and-medolife-rx-provide-updates-on-activities-and-plans
“It has been a difficult year full of new challenges for the Company and its staff,” said Dr. Mikaelian. “However, we want to make it clear to our investors and customers that we are working hard and not giving up. We see a path to achieve the goals we set for ourselves. We have a humble but loyal staff that believes in the success of its products and technology and who are working tirelessly to make Medolife a commercially successful biotechnology platform that will continue to focus on creating powerful drugs, cosmetics and supplements for a variety of uses and industries. I truly hope that, starting early next year, we can already achieve notable improvements in the overall operations of the Company. I want to apologize to our investors for the long silence, and I thank them from the bottom of my heart for the support and patience they have shown us.”
Let me ask you this question? Isn’t it time Arthur is replaced?
Flagged it ? I have no idea what you are referring to.
Arthur, It is time you step down and a qualified leader step in and take your place. I am sure several of us shareholders would be interested in covering their salary. That is if you have not been running a scam! Clearly you are way over your capabilities. Pat
This is a message I sent him yesterday on LinkedIn! PennyWorld / Grant must have not liked it and flagged it.
May 2023 bring new and great tidings...
https://finance.yahoo.com/news/quanta-medolife-rx-updates-activities-171200121.html
If this company is legitimate, it just needs a capable leader. Arthur has clearly shown he is over his head with his ability to run this business.
Clearly a class-action suit on behalf of shareholders is imperative to end this sharade.
Arthur, It is time you step down and a qualified leader step in and take your place. I am sure several of us shareholders would be interested in covering their salary. That is if you have not been running a scam! Clearly you are way over your capabilities. Pat
Maybe! He is still a dumb ass.
I disagree. If Arthur is clever enough to defraud the SEC, he is clever enough to do legitimate business. Add in that he has been through this before with Petlife and you have a preplanned scam.
Arthur is so far over his abilities it’s a sad situation.
It's funny that you called him to bullshit you over the phone since he can't put any more bullshit over any media for fear of criminal charges.
He is good at making it seem like something is about to happen. Remember the Dominican deal that was supposed to be done in Autumn '21 or the Mexican deal that was supposed to complete last winter? Stuff is always about to happen. It just never does. And it is pretty much impossible to strike out at everything unless you are doing absolutely nothing. I am surprised he did not try to get more money out of you.
I am sure they took their bonuses a long time ago! So what i wondering is which tropical island they are spending the New Year visiting? Nice of them to spend the remaining shareholder money.
Arthur is just stealing from all of us!
I have sent the slim several messages on LinkedIn! He doesn’t have the guts to respond. If the products work as they claim, the company would have been sold months ago.
All he does is bleed, pilfer, and dilute. Maybe someone can call him and get some more bullshit about how things are about to happen? Obviously, from the way the company is run, he does not believe a word of his own bullshit. If anything did ever happen, it would be too late shareholders with all the dilution in the meantime.
Looks like good reviews on Amazon for AELIA - on a side note Wishing everyone a happy New Years - also hopefully none were to adversely affected by the recent below freezing temperatures- here’s to 2023 bringing good tidings to all
https://www.amazon.com/product-reviews/B09H3QX8GD/ref=pd_sbs_cr_sccl_2_1/000-0000000-0000000?pd_rd_w=LR0T0&pf_rd_p=44b0dc04-f99a-4419-a406-9567d0fa03fe&pf_rd_r=598ZT9G2BAQJW3X19CMQ&pd_rd_r=4871dfb5-67d5-448b-8875-c99e423aac35&pd_rd_wg=hE9KM&pd_rd_i=B09H3QX8GD
Looks like another vacation day for Arthur! What an idiot.
There are several things that need to happen to him but they will not. He is playing chess and you have been playing checkers, mate. The SEC did what it was supposed to be done, take the Ponzi out of line. Nobody will come after anyone to size Assssss.... Unless you personally pay an expensive lawyer to get him locked up. Make the math
That will never happen. The SEC does not have the resources to go after little fries like QNTA. Their motto with little penny stocks is.... 'Buyer Beware'. 99% of the time, that's as far as they go with it. And the CEO's of tiny sub-penny stocks know it, so they play the odds and almost always win. All we can do is diversity, and use stops for protection.
Arthur needs to be held personally responsible and he needs to be sent prison. He has stolen millions from investors. Time the SEC makes him pay the price.
Of course they are!!! That is old news, unless you think they were hustling around with something else on the hood and acid money.. You know? Because it ain't falling from the sky their covered expenses. A.M and his amigos are parasites' sucking our money away monthly. He has a mansion and lambo and servant in the DR to feed, it is definitely not coming from his bank account or from scorpion venom sales
I agree with you completely! They are living off of shareholder money.
The revenues mysteriously went down from '20 to '21 without explanation. They may be doing more business than anyone thinks right along, including now, and just not declaring and sharing it with shareholders..
They can file and are not doing so. That, combined with the fact they were filing fraudulently when they were filing, tells us a lot.
Speaking of Aelia products, where is the money coming from to manufacture the product? Yes I know that's a question nobody can answer on here but it has me wondering. Then what happens when they're out of product?
Taking a tax loss isn’t an option for me ..
So, I’m holding long (not everyone’s choice / option etc … but it’s what is best for me).
So, in the meantime…. I’m keeping my eyes on any news, buying and sharing AELIA products with family and friends as gifts (because they work & folks like them)
And keeping optimism in my mind that despite Murphy law wreaking havoc on qnta … that they will like the little engine that could, with perseverance, find their way.
It wasn’t unfortunately double up quickly investment it looked like when I first bought in at 0.05 and saw go to 0.19 briefly
HOWEVER… the science and the products are good …
Everyone has to obviously do what’s best for themselves.
GLTA
Time to take it as a tax loss and move on! If the scam stock will even sell! Arthur needs to get taught a lesson he will never forget. The guy is a low life!
“At the best, it is worth far more than anyone realizes, and selling at this low point would be counterproductive. “
…. Good point
I have a feeling they are not considering a sale of the company due to the magnitude of fraud committed in false financials. Looking back at the past financials, this is the only reason I see they won’t try and sell the company.
There is probably a reason he is silent on the attorney's identity (not saying it is a good reason). I also think Arthur is sitting back and allowing the attorney to run things (just an educated guess). I can assure everyone the attorney is not doing this pro bono.
For some reason the attorney is not entertaining the idea of selling the company. What this all means? I cannot even hazard an educated guess at this point.
At the worst, the company is worthless and trying to sell it is a waste of time. The attorney and Arthur will pillage what they can before the courts shut it down.
At the best, it is worth far more than anyone realizes, and selling at this low point would be counterproductive.
Obviously, an investment deal has not been struck at this point because the terms are not to the Attorney's and Arthur's liking.
Arthur’s doesn’t even have the common sense to tell the investment community or shareholders who they have representing the company. He is a total idiot!
The attorney may be beating him to the punch for all we know. I suppose I am cynical but when an attorney becomes involved, I can't help but think their goal is to screw as many people as possible. while putting forth as little time and effort as possible. And after shareholders, trusty Arthur is the most vulnerable target.
The unknown attorney (Armenian?) is taking his cut too.
Something is very wrong that you would try to justify Arthur’s actions! He is just stealing everyone’s money. In my book he total scum.
It’s obvious they are running a scam! Any proceeds from sales is going directly into Arthur’s and Grants pockets.
We have no idea what the share structure is much less what is available. They purposely are not filing and were operating fraudulently, even when they were filing, according to the SEC which got them booted off the frikkin pink sheets. Evidently an unknown attorney is taking over and calling the shots while instructing Arthur to use a lot of words and say nothing. Also Arthur may not be able to file without incriminating himself.
Why would any investment group invest in QNTA with Arthur still involved. Today show us, he is living in a fantasy world. This stock will never get out a CE status by the SEC.
They will have money if they strike an investment deal. I don't feel that their products are attractive enough (from an ROI perspective) to persuade Big Pharm to invest in them. They have nothing that is FDA approved, so Big Pharm would need to see monster ROI before they would finance that operation. JMHO.
They have no cash / working capital and he is way over his head!
There are 2.5B in AS. Bring it back current and raise some capital. What's wrong with this CEO?
Only option is the sale of the company!
This going to come back alive again?
QNTA has no money! Selling the company is the only option. It the products work and they have magical cure for cancer, there should be several deep pocket pharmaceutical companies ready to buy them out.
Followers
|
114
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
13742
|
Created
|
03/12/18
|
Type
|
Free
|
Moderators |
Quanta for 2021 will be undergoing a name change to be announced shortly as well as Quanta is in the process of expanding its product line from 4 SKUs to 38 by summer. We will also be introducing all new branding with new color schemes, new packaging, and exciting celebrity endorsements for the pain relief products and a newly introduced beauty product line. Quanta will also be working on a men’s cosmetic line in conjunction with one of the celebrity endorsements planned for late 2021. The company has hired an advertising agency to help with the rollout of the new branding expected second quarter 2021. This will work in conjunction with a major push the company is on the path of with some major big box retail chains.
Quanta Basics
Quanta is a cutting-edge technology platform whose patented, proprietary technology harnesses advances in quantum biology to increase the potency of active ingredients. Currently, Quanta supports product formulations in pain management, anti-inflammation, skincare, agriculture, nutritional supplements, and plant-based consumables. Ultimately, Quanta’s mission is to deliver better, more effective ingredients to elevate product efficacy, reduce waste and facilitate healthier, more sustainable consumption.
The established resonance theory behind Quanta’s polarization process has many potential applications. From potentiating bio-ingredients to produce more-effective carbon-trapping plants to transformative anti-aging solutions Quanta’s technology has the opportunity to upend how commercial products are made and the benefits from them. Already we see multi-trillion-dollar global industries benefiting from Quanta’s technology.
Our proof of concept, Quanta’s market-leading CBD pain-relief rub (“Muscle Rub”), is only the first in a series of paradigm shift products to emerge from our labs. At the heart of its well-documented effectiveness is our proprietary “polarization” process, which uses electromagnetic force to markedly enhance bioactivity at the molecular level—a polarized active ingredient is more soluble and creates stronger bonds with the body’s receptors. This allows us to enhance ingredients so they work faster and more powerfully without the use of chemical by-products or cellular penetration. Quanta believes this natural solution has nearly limitless applications in the world of plant-based consumer products.
Quanta is involved in ambitious projects that we believe will reshape the next wave of climate science, sustainability, nutrition, and more. Having harnessed the technology of the future, Quanta is dedicated to bringing tomorrow’s health and wellness solutions to the billions in need today.
Discovery Synopsys
Using our product development process and business-to-business and direct-to-consumer sales approaches as a benchmark for future business, we developed the Quanta business model. Our technology’s unique ability to strengthen ingredients renders them more potent without added chemicals or penetrating cells means Quanta is in a first-of-its-kind position in the market. As the world’s first company focused on Quantum Biology we sit in a strong, but unique position in the market.
Our ability to increase ingredient efficacy by up to 500% means we are in a rare position to truly disrupt many areas of material science.
Quanta’s technology renders products superior to any on the market today. A 30% re-purchase rate (on one SKU alone) illustrates consumer appetite for the product.
Upcoming products and ventures will be designed to achieve or surpass this level of consumer benefit and uptake.
https://www.sec.gov/ix?doc=/Archives/edgar/data/1691430/000149315221008846/form10-k.htm
Management Team
Arthur Mikaelian, Ph.D.
Chairman & CEO
One of Dr. Arthur Mikaelian’s greatest scientific contributions and groundbreaking inventions is Quantum Physics and Quantum Biology-based polarization technology, which targets molecular structure of the main ingredients in synthetic medications or natural compounds, leading to the increased potency of liquid and solid compounds, which substantially increases their therapeutic effectiveness. Dr. Mikaelian’s polarization technology has been awarded U.S. Patent 8,097,284B2 as it pertains to the Polarized Scorpion Venom solution. For the past 20 years, Dr. Mikaelian has been independently actively studying stress hormones (cortisol, epinephrine), and the master gene’s (ATF3) indirect influence on cancer cell activity and tumor progression. His initial findings quickly led him to the innovative creation of a new generation of pharmaceutical and nutraceuticals drugs, as well as expanding his interests in cancer and oncology.
Dr. Mikaelian’s education began in 1984 at the 2nd Medical Institute of Moscow and continued at the Vernadsky University of Biosphere Knowledge in Moscow, where he earned his doctorate in Biological/NeuroPsychology; he then went on to complete his postdoctoral work at Vernadsky. Dr. Mikaelian has broad experience with Quantum Physic and Quantum Biology. He also earned an MBA from the University of Bologna in Italy.
Khalid Matalka, Ph.D., SI(ASCP)
Chief Scientific Officer
Professor Khalid Matalka received his BSc and MSc in Medical Technology in 1986 and 1988 from Yarmouk University, Jordan, and the University of Wisconsin-Milwaukee, USA. Then he received his Ph.D. in Pathology (Immunology and Cancer therapy) from Ohio State University, USA, in 1992. After finishing his Ph.D., Dr. Matalka joined Harvard Medical School as a Postdoctoral fellow till 1994. He is an American Board Certified as a Specialist in Immunology (SI-ASCP) and a member at the American Society for Cancer Research since 1994.
Dr. Matalka enrolled in academia as an assistant professor in 1995, then promoted to associate and then a professor in 2004. Prof. Matalka held a dean position at two different academic institutions. Besides, Prof. Matalka was a consultant for twenty years to a JPM pharmaceutical company and a hospital diagnostic laboratory. During those 22 years, Prof. Matalka was heavily involved in research mainly on immunomodulation, cancer research, and development of immunological assays. In 2016, he joined a pharmaceutical startup company named OncoTherapeutica, MA as a Chief Biologist. While there, Prof. Matalka was developing new potential drugs for the treatment of prostate cancer and melanoma. In March 2020, Prof. Matalka joined Medolife Corporation as Chief Scientific Officer (CSO) and, in February 2021, became the CSO of the newly established Medolife Rx.
Prof. Matalka has 65 publications in peer-reviewed international journals, and he is an Associate Editor of two and a member of the editorial board of several international journals. Prof. Matalka is known as an international reviewer in the fields of Cancer therapy, Immunomodulation, and Ethnopharmacology.
Grant Mikaelian
Executive Vice President
In 2013, Mr. Grant Mikaelian began working for an advanced biopharmaceutical company called Medolife. During his employment, he amassed a wide range of skills through managing various departments of the company. As a Marketing Sales Department Manager, he led many successful projects to improve customer experience through website development and design, enhanced customer support, streamlined ordering systems, configuration of B2C/B2B logistics, company rebranding, and preparation of marketing literature and presentations. He was later promoted to Operations Manager, overseeing and optimizing company departments on a larger scale. He was involved in production planning, project management of short and long-term goals, hiring prospective employees and contractors, corporate IT improvements, equipment procurement, international product registrations, due diligence preparation, and financial audits. He came to inspire confidence and began working closely with Dr. Arthur Mikaelian, CEO of Medolife. Soon after, Mr. Mikaelian was further promoted to Chief Business Development Officer. As the CBDO, he worked with existing and potential shareholders, was involved in domestic and international investment opportunities, managed multiple departments, increased company and product awareness, expanded product distribution channels, drafted Press Releases and articles, edited and proofread company literature, and more. Mr. Mikaelian is an organized leader with broad experiences in management and promotion of corporate growth.
Clemente Pascarella
Audit Committee
Christopher Rullan
Attorney for Mexico Division
Eduard Sahakyan
Head of R&D
Dr. Sahakyan started his career at Glendale Community College (GGC) as a lab technician for the biology department. He then pursued a biotechnology major at Pasadena City College (PCC). During his studies he interned at the Pasadena Bio Collaborative (PBC) Incubator as part of the LA Bioscience Hub research outreach program. Dr. Sahakyan worked with multiple companies including UCLA, Amgen and others during his summer internship. Upon completion, he was offered a permanent position at BCN (UCLA research collaborative) where he completed multiple projects, some of them are pending publication. In 2019, Dr. Sahakyan was offered a position in Medolife as a research associate. Within a year he was promoted to head scientist. Throughout this time, Dr. Sahakyan has worked on a number of company projects, which he presented at different local and national conferences. One of his bigger projects is the differentiation of embryonic stem cells into red blood cells. He continuously brings new ideas and initiatives to the company.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |